1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
Real-time Estimate Cboe Europe  -  06:02 2022-08-18 am EDT
10964.00 GBX   -0.35%
01:35aAstraZeneca Faces Sluggish COVID-19 Antibody Rollout Over Effectiveness Woes
MT
08/17MARKETSCREENER’S WORLD PRESS REVIEW : August 17, 2022
MS
08/17AstraZeneca and Merck - FDA Accepts Submission of Supplemental New Drug Application for LYNPARZA (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone for Patients With Metastatic Castration
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca to buy oncology firm TeneoTwo for up to $1.27 billion

07/05/2022 | 02:24am EDT
FILE PHOTO: Exterior photos of the North America headquarters of AstraZeneca

(Reuters) - AstraZeneca said on Tuesday it will acquire oncology firm TeneoTwo Inc in a deal worth up to $1.27 billion, including the company's initial stage T-cell engager.

The London-listed drugmaker plans to buy all outstanding equity of TeneoTwo for upfront payment of $100 million on deal close.

(Reporting by Yadarisa Shabong in Bengaluru; Editing by Sherry Jacob-Phillips)


ę Reuters 2022
All news about ASTRAZENECA PLC
01:35aAstraZeneca Faces Sluggish COVID-19 Antibody Rollout Over Effectiveness Woes
MT
08/17MARKETSCREENER’S WORLD PRESS REVIEW : August 17, 2022
MS
08/17AstraZeneca and Merck - FDA Accepts Submission of Supplemental New Drug Application for..
AQ
08/17Sanofi trial failure ends development of breast cancer treatment amcenestrant
RE
08/17Sanofi trial failure halts work on breast cancer treatment amcenestrant
RE
08/16Australia biotech giant CSL reports profit dip, flags cost spiral
RE
08/16Lynparza in combination with abiraterone granted Priority Review in the US for patient..
AQ
08/16AstraZeneca Sues Former Executive to Prevent Potential Therapy Data Leak to Rival GSK
MT
08/16AstraZeneca Granted FDA Priority Review for Prostate Cancer Combination Therapy
MT
08/16LYNPARZA« (olaparib) in combination with abiraterone granted Priority Review in the US ..
BU
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2022 44 238 M - -
Net income 2022 4 399 M - -
Net Debt 2022 24 039 M - -
P/E ratio 2022 47,3x
Yield 2022 2,22%
Capitalization 205 B 205 B -
EV / Sales 2022 5,19x
EV / Sales 2023 4,82x
Nbr of Employees 83 100
Free-Float 96,4%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Last Close Price 132,52 $
Average target price 144,13 $
Spread / Average Target 8,76%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC26.78%205 344
JOHNSON & JOHNSON-2.04%440 598
ELI LILLY AND COMPANY14.70%301 034
PFIZER, INC.-16.56%276 521
ROCHE HOLDING AG-16.47%273 077
ABBVIE INC.4.46%250 080